niacinamide has been researched along with sincalide in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (25.00) | 18.2507 |
| 2000's | 1 (25.00) | 29.6817 |
| 2010's | 2 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Itoh, M; Miyamoto, T; Noguchi, Y; Yokochi, K | 1 |
| Damgé, P; Kuntz, E; Pinget, M | 1 |
| Alsaied, OA; Banerjee, S; Chugh, R; Jensen, EH; Krosch, TC; Saluja, A; Sangwan, V; Vickers, SM | 1 |
| Chen, YL; Ding, X; Gao, Z; Gu, T; Liu, W; Qu, M; Wang, W; Wu, X; Xu, L; Zhang, W | 1 |
4 other study(ies) available for niacinamide and sincalide
| Article | Year |
|---|---|
Role of intracellular Ca2+ and the calmodulin messenger system in pepsinogen secretion from isolated rabbit gastric mucosa.
Topics: Animals; Calcium; Calmodulin; Carbachol; Colforsin; Dose-Response Relationship, Drug; Gastric Mucosa; Niacinamide; Nicorandil; Organ Culture Techniques; Pepsinogens; Rabbits; Second Messenger Systems; Sincalide; Sulfonamides; Verapamil | 1992 |
Cholecystokinin octapeptide: a potential growth factor for pancreatic beta cells in diabetic rats.
Topics: Animals; Blood Glucose; Cell Division; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Drug Evaluation, Preclinical; Glucose Tolerance Test; Insulin; Insulin Secretion; Islets of Langerhans; Male; Niacinamide; Rats; Rats, Wistar; Sincalide; Streptozocin | 2004 |
Sorafenib and triptolide as combination therapy for hepatocellular carcinoma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Hepatocellular; Caspase 3; Caspase 7; Cell Line, Tumor; Cell Proliferation; Cell Survival; Diterpenes; Drug Synergism; Epoxy Compounds; Humans; Liver Neoplasms; Liver Neoplasms, Experimental; Mice; Mice, Nude; Models, Biological; NF-kappa B p50 Subunit; Niacinamide; Organophosphates; Phenanthrenes; Phenylurea Compounds; Prodrugs; Signal Transduction; Sincalide; Sorafenib; Translational Research, Biomedical; Xenograft Model Antitumor Assays | 2014 |
Sorafenib exerts an anti-keloid activity by antagonizing TGF-β/Smad and MAPK/ERK signaling pathways.
Topics: Adult; Cell Cycle; Cell Movement; Cell Proliferation; Cells, Cultured; Female; Fibroblasts; Humans; Keloid; Male; Middle Aged; Mitogen-Activated Protein Kinases; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Signal Transduction; Sincalide; Smad Proteins; Sorafenib; Transforming Growth Factor beta; Young Adult | 2016 |